Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 144 of 153 entries
Sorted by: Best Match Show Resources per page
SGLT2 Inhibitors in Liver Patients.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Hsiang JC, Wong VW.
PMID: 32428710
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16.

No abstract available.

Cite
Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol. 2020;18(10):2168-2172.e2doi: 10.1016/j.cgh.2020.05.021.
Hsiang, J. C., & Wong, V. W. (2020). SGLT2 Inhibitors in Liver Patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 18(10), 2168-2172.e2. https://doi.org/10.1016/j.cgh.2020.05.021
Hsiang, John Chen, and Wong, Vincent Wai-Sun. "SGLT2 Inhibitors in Liver Patients." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 18,10 (2020): 2168-2172.e2. doi: https://doi.org/10.1016/j.cgh.2020.05.021
Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16. PMID: 32428710.
Copy Download .nbib Format: NLM
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.

Diabetes research and clinical practice

Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I.
PMID: 31121272
Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D) that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV...

Cite
Schernthaner G, Wanner C, Jurišić-Eržen D, et al. CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Res Clin Pract. 2019;153:30-40doi: 10.1016/j.diabres.2019.05.013.
Schernthaner, G., Wanner, C., Jurišić-Eržen, D., Guja, C., Gumprecht, J., Jarek-Martynowa, I. R., Karasik, A., Lalić, N., Mankovsky, B. N., Prázný, M., Tankova, T., Tsur, A., Wascher, T. C., & Wittmann, I. (2019). CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes research and clinical practice, 15330-40. https://doi.org/10.1016/j.diabres.2019.05.013
Schernthaner, Guntram, et al. "CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle." Diabetes research and clinical practice vol. 153 (2019): 30-40. doi: https://doi.org/10.1016/j.diabres.2019.05.013
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I. CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20. PMID: 31121272.
Copy Download .nbib Format: NLM
[No title available]

Journal of biomolecular structure & dynamics

Sharma S, Srivastav S, Singh G, Singh S, Malik R, Alam MM, Shaqiquzamman M, Ali S, Akhter M.
PMID: 32248758
J Biomol Struct Dyn. 2021 Apr;39(6):2118-2132. doi: 10.1080/07391102.2020.1751714. Epub 2020 Apr 20.

Identification of new DPP-IV inhibitors by integrating validated

Cite
Sharma S, Srivastav S, Singh G, et al. . J Biomol Struct Dyn. 2020;39(6):2118-2132doi: 10.1080/07391102.2020.1751714.
Sharma, S., Srivastav, S., Singh, G., Singh, S., Malik, R., Alam, M. M., Shaqiquzamman, M., Ali, S., & Akhter, M. (2021). . Journal of biomolecular structure & dynamics, 39(6), 2118-2132. https://doi.org/10.1080/07391102.2020.1751714
Sharma, Shweta, et al. "." Journal of biomolecular structure & dynamics vol. 39,6 (2021): 2118-2132. doi: https://doi.org/10.1080/07391102.2020.1751714
Sharma S, Srivastav S, Singh G, Singh S, Malik R, Alam MM, Shaqiquzamman M, Ali S, Akhter M. . J Biomol Struct Dyn. 2021 Apr;39(6):2118-2132. doi: 10.1080/07391102.2020.1751714. Epub 2020 Apr 20. PMID: 32248758.
Copy Download .nbib Format: NLM
A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.

Expert review of clinical pharmacology

Shah SR, Iqbal SM, Alweis R, Roark S.
PMID: 30488734
Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03.

INTRODUCTION: Type 2 diabetes (T2D) is an independent risk factor for heart failure (HF). With concomitant T2D and HF, recent data suggests an incremental risk of cardiovascular death and hospitalization for HF, as compared to patients with HF without...

Cite
Shah SR, Iqbal SM, Alweis R, et al. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2018;12(1):45-52doi: 10.1080/17512433.2019.1552830.
Shah, S. R., Iqbal, S. M., Alweis, R., & Roark, S. (2019). A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert review of clinical pharmacology, 12(1), 45-52. https://doi.org/10.1080/17512433.2019.1552830
Shah, Syed Raza, et al. "A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs." Expert review of clinical pharmacology vol. 12,1 (2019): 45-52. doi: https://doi.org/10.1080/17512433.2019.1552830
Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03. PMID: 30488734.
Copy Download .nbib Format: NLM
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?.

Expert review of clinical pharmacology

Pafili K, Papanas N.
PMID: 31232616
Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30.

No abstract available.

Cite
Pafili K, Papanas N. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Rev Clin Pharmacol. 2019;12(8):693-695doi: 10.1080/17512433.2019.1635453.
Pafili, K., & Papanas, N. (2019). Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert review of clinical pharmacology, 12(8), 693-695. https://doi.org/10.1080/17512433.2019.1635453
Pafili, K, and Papanas, N. "Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?." Expert review of clinical pharmacology vol. 12,8 (2019): 693-695. doi: https://doi.org/10.1080/17512433.2019.1635453
Pafili K, Papanas N. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30. PMID: 31232616.
Copy Download .nbib Format: NLM
The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply.

The lancet. Diabetes & endocrinology

Davies J, Linklater S, Mitchell F.
PMID: 25702246
Lancet Diabetes Endocrinol. 2015 Mar;3(3):168-9. doi: 10.1016/S2213-8587(15)00007-8.

No abstract available.

Cite
Davies J, Linklater S, Mitchell F. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply. Lancet Diabetes Endocrinol. 2015;3(3):168-9doi: 10.1016/S2213-8587(15)00007-8.
Davies, J., Linklater, S., & Mitchell, F. (2015). The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply. The lancet. Diabetes & endocrinology, 3(3), 168-9. https://doi.org/10.1016/S2213-8587(15)00007-8
Davies, Justine, et al. "The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply." The lancet. Diabetes & endocrinology vol. 3,3 (2015): 168-9. doi: https://doi.org/10.1016/S2213-8587(15)00007-8
Davies J, Linklater S, Mitchell F. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply. Lancet Diabetes Endocrinol. 2015 Mar;3(3):168-9. doi: 10.1016/S2213-8587(15)00007-8. PMID: 25702246.
Copy Download .nbib Format: NLM
[Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes].

Der Internist

Blüher M.
PMID: 25636953
Internist (Berl). 2015 Feb;56(2):143-8, 150-2. doi: 10.1007/s00108-014-3534-6.

There is strong epidemiological evidence for an association between increased body weight and a higher incidence of type 2 diabetes. Moreover, reduction in body weight may delay the onset of type 2 diabetes. The basic therapy of type 2...

Cite
Blüher M. Medikamentöse Therapie vs. bariatrische Chirurgie bei Adipositas und Typ-2-Diabetes. [Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes]. Internist (Berl). 2015;56(2):143-8, 150-2doi: 10.1007/s00108-014-3534-6.
Blüher, M. (2015). Medikamentöse Therapie vs. bariatrische Chirurgie bei Adipositas und Typ-2-Diabetes. [Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes]. Der Internist, 56(2), 143-8, 150-2. https://doi.org/10.1007/s00108-014-3534-6
Blüher, M. "Medikamentöse Therapie vs. bariatrische Chirurgie bei Adipositas und Typ-2-Diabetes." [Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes]. Der Internist vol. 56,2 (2015): 143-8, 150-2. doi: https://doi.org/10.1007/s00108-014-3534-6
Blüher M. Medikamentöse Therapie vs. bariatrische Chirurgie bei Adipositas und Typ-2-Diabetes. [Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes]. Internist (Berl). 2015 Feb;56(2):143-8, 150-2. doi: 10.1007/s00108-014-3534-6. German. PMID: 25636953.
Copy Download .nbib Format: NLM
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association.

The Korean journal of internal medicine

Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH.
PMID: 29056038
Korean J Intern Med. 2017 Nov;32(6):947-958. doi: 10.3904/kjim.2017.298. Epub 2017 Oct 23.

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in...

Cite
Ko SH, Hur KY, Rhee SY, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean J Intern Med. 2017;32(6):947-958doi: 10.3904/kjim.2017.298.
Ko, S. H., Hur, K. Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S. O., Lee, B. W., Kim, H. J., Choi, K. M., Kim, J. H. (2017). Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. The Korean journal of internal medicine, 32(6), 947-958. https://doi.org/10.3904/kjim.2017.298
Ko, Seung-Hyun, et al. "Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association." The Korean journal of internal medicine vol. 32,6 (2017): 947-958. doi: https://doi.org/10.3904/kjim.2017.298
Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean J Intern Med. 2017 Nov;32(6):947-958. doi: 10.3904/kjim.2017.298. Epub 2017 Oct 23. PMID: 29056038; PMCID: PMC5668403.
Copy Download .nbib Format: NLM
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.

Current drug safety

Singh M, Sharma R, Kumar A.
PMID: 30727912
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.

BACKGROUND: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is...

Cite
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93doi: 10.2174/1574886314666190206164647.
Singh, M., Sharma, R., & Kumar, A. (2019). Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current drug safety, 14(2), 87-93. https://doi.org/10.2174/1574886314666190206164647
Singh, Mahakpreet, et al. "Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus." Current drug safety vol. 14,2 (2019): 87-93. doi: https://doi.org/10.2174/1574886314666190206164647
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647. PMID: 30727912.
Copy Download .nbib Format: NLM
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.

Diabetes & metabolism

Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM.
PMID: 29477373
Diabetes Metab. 2018 Mar;44(2):112-120. doi: 10.1016/j.diabet.2018.01.017. Epub 2018 Feb 07.

AIMS: Our aim was to compare Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) to Dipeptidyl peptidase-4 inhibitors (DPP-4i) as add-on therapy to metformin.METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We...

Cite
Mishriky BM, Tanenberg RJ, Sewell KA, et al. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(2):112-120doi: 10.1016/j.diabet.2018.01.017.
Mishriky, B. M., Tanenberg, R. J., Sewell, K. A., & Cummings, D. M. (2018). Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes & metabolism, 44(2), 112-120. https://doi.org/10.1016/j.diabet.2018.01.017
Mishriky, B M, et al. "Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis." Diabetes & metabolism vol. 44,2 (2018): 112-120. doi: https://doi.org/10.1016/j.diabet.2018.01.017
Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018 Mar;44(2):112-120. doi: 10.1016/j.diabet.2018.01.017. Epub 2018 Feb 07. PMID: 29477373.
Copy Download .nbib Format: NLM
Antidiabetic medications in patients with heart failure.

Minerva endocrinologica

Samia El Hayek MM, Beydoun MF, Azar ST.
PMID: 27195949
Minerva Endocrinol. 2017 Mar;42(1):53-63. doi: 10.23736/S0391-1977.16.02349-X. Epub 2016 May 19.

Diabetes mellitus increases the mortality secondary to heart failure independent of hypertension and coronary artery disease. Several hypoglycemic agents are used to achieve glycemic control, of which several classes however still raise controversies in terms of safety in patients...

Cite
Samia El Hayek MM, Beydoun MF, Azar ST. Antidiabetic medications in patients with heart failure. Minerva Endocrinol. 2016;42(1):53-63doi: 10.23736/S0391-1977.16.02349-X.
Samia El Hayek, M. M., Beydoun, M. F., & Azar, S. T. (2017). Antidiabetic medications in patients with heart failure. Minerva endocrinologica, 42(1), 53-63. https://doi.org/10.23736/S0391-1977.16.02349-X
Samia El Hayek, Marylene M, et al. "Antidiabetic medications in patients with heart failure." Minerva endocrinologica vol. 42,1 (2017): 53-63. doi: https://doi.org/10.23736/S0391-1977.16.02349-X
Samia El Hayek MM, Beydoun MF, Azar ST. Antidiabetic medications in patients with heart failure. Minerva Endocrinol. 2017 Mar;42(1):53-63. doi: 10.23736/S0391-1977.16.02349-X. Epub 2016 May 19. PMID: 27195949.
Copy Download .nbib Format: NLM
[What do they offer new oral antibiotics?].

Atencion primaria

Laudo Pardos C, Puigdevall Gallego V.
PMID: 27154325
Aten Primaria. 2016 May;48(5):279-80. doi: 10.1016/j.aprim.2016.04.002.

No abstract available.

Cite
Laudo Pardos C, Puigdevall Gallego V. ¿Qué aportan los nuevos antidiabéticos orales? [What do they offer new oral antibiotics?]. Aten Primaria. 2016;48(5):279-80doi: 10.1016/j.aprim.2016.04.002.
Laudo Pardos, C., & Puigdevall Gallego, V. (2016). ¿Qué aportan los nuevos antidiabéticos orales? [What do they offer new oral antibiotics?]. Atencion primaria, 48(5), 279-80. https://doi.org/10.1016/j.aprim.2016.04.002
Laudo Pardos, Consuelo, and Puigdevall Gallego, Víctor. "¿Qué aportan los nuevos antidiabéticos orales?" [What do they offer new oral antibiotics?]. Atencion primaria vol. 48,5 (2016): 279-80. doi: https://doi.org/10.1016/j.aprim.2016.04.002
Laudo Pardos C, Puigdevall Gallego V. ¿Qué aportan los nuevos antidiabéticos orales? [What do they offer new oral antibiotics?]. Aten Primaria. 2016 May;48(5):279-80. doi: 10.1016/j.aprim.2016.04.002. Spanish. PMID: 27154325; PMCID: PMC6877884.
Copy Download .nbib Format: NLM
Showing 133 to 144 of 153 entries